A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsenovil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy

Grants and Contracts Details

StatusFinished
Effective start/end date7/9/196/4/20

Funding

  • UCB Pharma (domestic): $30,878.00